ArticleJMIR cancer2026
Clinical Feasibility of Six Inflammatory Markers for Predicting the Mortality of Patients With Cancer: Longitudinal Study.
Article in JMIR cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Emerging evidence indicates that inflammation plays a crucial role in cancer prognosis. Inflammatory response biomarkers are recognized as promising prognostic factors for mortality in patients with cancer. Objective: This study aims to evaluate the prognostic significance of the systemic inflammatory response index (SIRI), systemic immune-inflammation index (SII), platelet-to-lymphocyte ratio (PLR), neutrophil-to-lymphocyte ratio (NLR), inflammatory prognostic index (IPI), and C-reactive protein-albumin-lymphocyte (CALLY) index. Methods: Weighted Cox regression analyses, restricted cubic spline models, Kaplan-Meier survival curves, and receiver operating characteristic analyses were performed to assess the predictive value of the 6 inflammatory markers for mortality. Subgroup analyses and sensitivity analyses were conducted to examine associations within specific subpopulations. Results: Cox regression models demonstrated that SIRI, NLR, IPI, and CALLY were significant predictors of all-cause mortality (tertile 3 vs tertile 1; hazard ratio [HR]: SIRI: 1.72, 95% CI 1.29-2.27; NLR: 1.33, 95% CI 1.02-1.74; IPI: 1.48, 95% CI 1.14-1.92; CALLY: 0.66, 95% CI 0.51-0.85). IPI (HR 1.91, 95% CI 1.11-3.27) and CALLY (HR 0.53, 95% CI 0.31-0.90) were significantly associated with cancer-specific mortality, whereas only SIRI was able to predict cardiovascular mortality (P value for trend=.04). Dose-response relationships were observed between the 6 inflammatory markers and mortality outcomes. Kaplan-Meier survival curves further illustrated significant differences between tertile groups (log-rank test, P<.001). The 6 inflammatory indices exhibited moderate predictive ability for all-cause mortality. IPI yielded the highest area under the curve (AUC) for cancer-specific mortality (AUC=0.6338), and SIRI was the most efficient predictor of cardiovascular mortality (AUC=0.687). No significant interactions were observed between the 6 inflammatory markers and most subgroup variables. Conclusions: SIRI, NLR, IPI, and CALLY represent convenient and cost-effective prognostic tools for predicting mortality in patients with cancer. In contrast, SII and PLR may not be reliable prognostic biomarkers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.